Efforts to mitigate the prescription drug abuse epidemic and activities surrounding DSCSA implementation once again top the list of priorities HDA will be addressing in the year ahead, according to HDA President and CEO John M. Gray. Mr. Gray provided his perspective, along with other healthcare supply chain leaders, as part of Chain Drug Review’s annual “Pharmacy Outlook” feature, published in the January 1 issue.
“While [HDA’s] policy priorities for 2018 are similar to those of past years,” said Mr. Gray, “For our pharmaceutical distributor members, many of these issues — such as fighting prescription drug abuse and implementing pharmaceutical traceability — are at critical junctures. I believe it will take perseverance and partnership, with our supply chain peers and those that regulate our industry, to forge a successful path forward on these fronts and others.”
In the column, Gray also highlights that the Alliance also will be staying abreast of policies surrounding prescription drug importation as well as the introduction of additional tax policies as the year unfolds. He also highlighted a few of HDA’s initiatives, including the integration of the Pharmaceutical Cargo Security Coalition (PCSC), announced late last year, as well as the Origin GTIN repository service and the Alliance’s work on a Verification Router Service solution to process serialized saleable returns under the DSCSA.
ABOUT THE HEALTHCARE DISTRIBUTION ALLIANCE
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.